Speaker: 

Jacob Laser, MD Staff Physician, Geisinger - has nothing to disclose.

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• Learn about the available CD20 antagonist drugs currently being used to treat RRMS
• Learn about the risks and benefits of starting Kesimpta as first line agent vs transitioning to Kesimpta after several years on Aubagio
• Discuss possible future implications of Kesimpta as a subcutanious CD20 antagonist on clinical practice for treating RRM

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Dana Vanino, DO; Cortney Houtz, LPN; Joy Hill, RN and Kristy Heim have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPPA compliant.